NCT03462680View on ClinicalTrials.gov

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

NACompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 28, 2016

Primary Completion Date

April 23, 2020

Study Completion Date

April 23, 2020

Conditions
Parkinson's Disease
Interventions
DIETARY_SUPPLEMENT

niacin

Niacin or nicotinic acid 250 mg tablets

OTHER

placebo

placebo tablet

Trial Locations (1)

30904

Charlie Norwood VA Medical Center, Augusta, GA, Augusta

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures | Biotech Hunter | Biotech Hunter